Analyst Price Target is $144.18
▲ +14.50% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Quest Diagnostics in the last 3 months. The average price target is $144.18, with a high forecast of $160.00 and a low forecast of $130.00. The average price target represents a 14.50% upside from the last price of $125.92.
Current Consensus is
Hold
The current consensus among 11 investment analysts is to hold stock in Quest Diagnostics. This Hold consensus rating has held steady for over two years.
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Read More
